Patterns of Clinical Management of Atopic Dermatitis: A Survey of Three Physician Specialties in the Middle East

Alfred Ammoury,[1] Ahmed Ameen,[2] Mahira Hamdy El Sayed,[3] Sultan Al-Khenaizan,[4] Nehal Hassan,[5] Marcelle Ghoubar[6]

[1]Division of Dermatology, Saint George Hospital University Medical Center, Beirut, Lebanon

[2]NMC Specialty Hospital, Abu Dhabi, United Arab Emirates

[3]Department of Venereology and Andrology, Faculty of Medicine, Ain Shams University, Cairo, Egypt

[4]Division of Dermatology, King Abdulaziz Medical City in Riyadh, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia

[5]Medical Affairs, Pfizer BVBA, Cairo, Egypt

[6]Medical Affairs, Pfizer Gulf FZ LLC, Beirut, Lebanon

Corresponding Author

Marcelle Ghoubar

Sin El Fil, Lebanon Central, 2nd floor

Phone: +9613014117

Email: marcelle.ghoubar@pfizer.com

Supplementary Material

Table S1. Percentage (rounded up) of patients receiving different types of atopic dermatitis therapy by prescribing physician country

Treatments (%)	**Mild-to-Moderate AD**					**Moderate-to-Severe AD**				
	Overall	**Lebanon**	**UAE**	**Saudi Arabia**	**Egypt**	**Overall**	**Lebanon**	**UAE**	**Saudi Arabia**	**Egypt**
Topical corticosteroids	57	57	59	52	59	62	62	64	66	54
Emollients only	40	39	41	41	40	28	25	30	36	22
Topical calcineurin inhibitors	25	25	30	22	24	30	30	34	28	26
Oral corticosteroids	16	14	11	18	20	36	32	25	33	52
Topical PDE4 inhibitors	11	9	8	12	16	15	13	10	17	18
Other oral systemics	10	6	8	10	16	17	9	11	16	32

Phototherapy	8	6	8	7	12	15	12	15	12	21
Cyclosporin	8	5	3	8	13	14	11	9	18	19
Oral JAK inhibitors	7	6	4	8	12	12	11	9	11	17
Methotrexate	7	5	4	8	12	14	12	11	16	18
Biologics	7	6	7	6	9	16	11	21	12	22
Other immunosuppressants	7	4	4	8	12	12	7	10	13	18

AD atopic dermatitis, *JAK* Janus kinase, *PDE4* phosphodiesterase 4, UAE United Arab Emirates

Table S2. Physician-identified unmet needs in the treatment of mild-to-moderate and moderate-to-severe atopic dermatitis by physician specialty (percentages are rounded up)

Treatments (%)	**Mild-to-Moderate AD**				**Moderate-to-Severe AD**			
	Overall	**Dermatology**	**Pediatrics**	**Primary Care/FM**	**Overall**	**Dermatology**	**Pediatrics**	**Primary Care/FM**
Treatments with better efficacy profile	38	34	44	38	35	33	43	31
Treatments with better safety profile	37	43	34	30	38	38	44	32
Treatments with faster onset of action	37	32	46	38	36	36	40	32

Treatment with long-term control of the disease	26	30	24	21	26	26	23	31
Treatments with more favorable dosing schedules	22	21	16	27	18	23	16	11
Advanced systemic treatment used as monotherapy with no need for combination with topical treatments	20	19	19	24	33	38	24	34

Treatments With novel mechanism of action	18	20	19	15	16	14	14	20
Advanced systemic treatments with oral route of administration	18	19	15	18	26	23	25	33
Limited approved treatment options in country	17	19	13	15	22	22	20	26

None; there are no unmet needs	8	6	8	10	4	3	5	7

Each physician indicated their top 3 unmet needs.

AD atopic dermatitis, *FM* family medicine

Table S3. Physician-identified unmet needs in the treatment of mild-to-moderate and moderate-to-severe atopic dermatitis by physician country (percentages are rounded up)

Treatments (%)	Mild-to-Moderate AD					Moderate-to-Severe AD				
	Overall	**Lebanon**	**UAE**	**Saudi Arabia**	**Egypt**	**Overall**	**Lebanon**	**UAE**	**Saudi Arabia**	**Egypt**
Treatments with better efficacy profile	38	38	35	41	37	35	38	31	32	38
Treatments with better safety profile	37	48	37	26	38	38	41	46	25	40
Treatments with faster onset of action	37	49	35	34	30	36	44	28	35	36

Treatment with long-term control of the disease	26	32	35	20	17	26	35	30	19	20
Treatments with more favorable dosing schedules	22	20	17	27	22	18	21	19	19	14
Advanced systemic treatment used as monotherapy with no need for combination with topical treatments	20	19	13	31	17	33	34	31	38	30
Treatments with novel mechanism of action	18	20	19	17	17	16	10	9	24	21

Advanced systemic treatments with oral route of administration	18	20	18	18	14	26	30	33	25	16
Limited approved treatment options in country	17	15	16	26	10	22	24	18	29	17
None; there are no unmet needs	8	3	8	5	15	4	1	8	1	9

Each physician indicated their top 3 unmet needs.

AD atopic dermatitis, *UAE* United Arab Emirates

Table S4. Physician-reported average rating for the importance of expected features of new atopic dermatitis treatments by physician specialty

Treatments	Overall	Dermatology	Pediatrics	Primary Care/FM
Long-term control of the disease	5.9	6.1	5.7	5.7
Efficacy in itch/pain reduction	5.7	5.8	5.5	5.5
Fast onset of action	5.5	5.6	5.4	5.4
Tolerable safety profile	5.4	5.6	5.1	5.3
Skin barrier restoration	5.3	5.6	5.1	5.0
Can be used as monotherapy	5.0	5.0	5.0	5.1
Oral route of administration	4.6	4.9	4.3	4.4

FM family medicine

Table S5. Physician-reported average rating for the importance of expected features of new atopic dermatitis treatments by physician country

Treatments	Overall	Lebanon	UAE	Saudi Arabia	Egypt
Long-term control of the disease	5.9	6.2	5.7	6.1	5.8
Efficacy in itch/pain reduction	5.7	6.1	5.5	6.0	5.1
Fast onset of action	5.5	5.8	5.2	5.7	5.3
Tolerable safety profile	5.4	5.7	5.3	5.5	5.1
Skin barrier restoration	5.3	5.8	5.5	5.6	4.4
Can be used as monotherapy	5.0	5.3	4.9	5.2	4.8
Oral route of administration	4.6	4.8	4.4	5.0	4.3

UAE United Arab Emirates

Fig. S1. Percentage (rounded up) of atopic dermatitis patients seen in a typical 4-month period based on age distribution by (a) physician specialty and (b) country



FM family medicine, *UAE* United Arab Emirates

Fig. S2. Methods used to assess remission in atopic dermatitis by (a) physician specialty and (b) country. Percentages are rounded up



EASI Eczema Area and Severity Index, *FM* family medicine, *IGA* Investigator's Global Assessment, *ISGA* Investigator's Static Global Assessment, *SCORAD* SCORing Atopic Dermatitis, *UAE* United Arab Emirates

Fig. S3. Approach to treating flares in patients with mild-to-moderate atopic dermatitis by (a) physician specialty and (b) country. Percentages are rounded up



FM family medicine, *PDE4* phosphodiesterase 4, *TCI* topical calcineurin inhibitor, *UAE* United Arab Emirates

Fig. S4. Therapeutic approach to treating infected lesions in patients with atopic dermatitis by (a) physician specialty and (b) country. Percentages are rounded up



FM family medicine, *UAE* United Arab Emirates

Fig. S5. Percentage (rounded up) of physicians that use proactive therapy in managing mild-to-moderate atopic dermatitis by (a) physician specialty and (b) country



FM family medicine, *UAE* United Arab Emirates

Fig. S6. Percentage (rounded up) of physician likelihood of prescribing systemic Janus kinase inhibitors for patients with moderate-to-severe atopic dermatitis by (a) physician specialty and (b) country (on a scale of 1 [least likely] to 7 [most likely])



FM family medicine, *UAE* United Arab Emirates